One Biosciences, a trailblazing biotech company at the intersection of single-cell analysis and artificial intelligence, has successfully raised $17.38 million (€16 million) in a Series A funding round. The capital will accelerate the company’s mission to decode cellular behavior and develop highly targeted therapeutics, particularly in oncology and immunology.

The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures - a blend of life sciences specialists and tech-forward backers. At the helm is Hedi Ben Brahim, whose leadership bridges world-class science with commercial scale. Backed by Institut Pasteur’s foundational science, Brahim and his team are translating deep single-cell data into next-generation therapeutics, unlocking targets that traditional discovery pipelines often miss.

Redefining Therapeutic Discovery with AI and Single-Cell Biology

Founded in Paris, One Biosciences operates at the convergence of computational biology and molecular science. Its proprietary platform integrates single-cell sequencing, spatial transcriptomics, and machine learning to uncover cellular mechanisms that traditional methods often miss.

The startup’s approach allows scientists to observe gene expression on a per-cell basis, revealing the intricacies of disease heterogeneity. This is particularly valuable in cancer, where identifying resistant cell populations can be the difference between remission and relapse. By using AI to analyze terabytes of single-cell data, One Biosciences can flag druggable targets with unparalleled resolution - transforming the therapeutic development process from reactive to predictive.

This funding milestone will support the expansion of the company’s R&D infrastructure, recruitment of AI and biology talent, and advancement of its internal therapeutic programs. The company also intends to pursue strategic partnerships with pharmaceutical companies seeking deeper molecular insights into patient response variability.

The Shift Toward “Cellular Intelligence” in Pharma

While large pharmaceutical companies have long relied on bulk RNA-sequencing and generalized models of disease, the shift toward single-cell technologies introduces a new paradigm: one where treatments can be designed not for the “average” patient, but for the distinct molecular profiles of subpopulations within tumors or inflamed tissues.

One Biosciences calls this approach “cellular intelligence.” By capturing the behaviors of thousands of individual cells simultaneously, the company aims to develop therapies that are not only personalized but also precise in their targeting mechanisms. This shift challenges pharma companies to rethink how they validate targets and design trials.

And here lies a lesson for every founder: solving a complex problem isn’t just about building better tools - it’s about shifting the framework entirely. The One Biosciences team didn’t merely improve diagnostics or streamline R&D pipelines; they challenged the very assumption that bulk data is sufficient. That’s the kind of thinking that separates iterative startups from transformational ones. Founders who want to lead markets, not just participate in them, should stop optimizing legacy processes and instead start asking: “What assumption is everyone else making - and what happens if I flip it?”

Backed by Scientific Legacy, Fueled by Computational Firepower

One Biosciences’ roots trace back to the Institut Pasteur, a globally renowned research center known for breakthroughs in virology, microbiology, and immunology. This scientific DNA, paired with modern machine learning architecture, gives the company a dual advantage: credibility among researchers and speed in algorithmic iteration.

The company’s core scientific leadership is composed of experts in oncology, bioinformatics, and translational medicine. Their pipeline includes both internal therapeutic programs and collaborative projects with pharma partners, allowing the team to validate discoveries in both academic and commercial contexts.

What also sets the team apart is its belief in vertical integration. From sample prep to data analysis and candidate identification, One Biosciences owns every step. This level of control reduces friction, accelerates discovery, and ensures that insights don’t get lost between outsourced vendors or siloed departments.

A New Era of Human-Centric Drug Design

Beyond the data and diagnostics, One Biosciences is pushing toward a more ethical and effective form of drug development. Its platform minimizes animal testing by using patient-derived organoids and digital twins to model disease progression. In effect, the company is helping move the industry toward a future where experimentation is safer, faster, and more predictive.

This aligns with broader industry shifts: regulators are increasingly rewarding companies that use more humane and data-efficient methods, and payers are pushing for drugs that demonstrate efficacy in the real world - not just in clinical silos.

What’s Next for One Biosciences?

With the new funding, One Biosciences will scale its internal R&D engine and accelerate the discovery of first-in-class and best-in-class molecules for diseases with high unmet needs. The team is also focused on global expansion, particularly in the U.S. and Asia, where precision medicine adoption is growing rapidly.

Additionally, the startup plans to launch a series of public-private research initiatives to further explore the role of single-cell biology in neurodegeneration, autoimmune conditions, and rare diseases.

By building a unified platform where biology, data science, and clinical impact converge, One Biosciences is poised not only to make headlines—but to redefine how the world understands and treats complex disease.